Jiangsu Hengrui’s RGL-193 Receives NMPA Greenlight for Parkinson’s Disease Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China and listed as...
Drug
Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment
The Center for Drug Evaluation (CDE) has indicated that Novartis (NYSE: NVS), the Swiss pharmaceutical...
Pfizer’s Talzenna Combo Shows Improved Survival in mCRPC Patients, According to TALAPRO-2 Study
Pfizer Inc. (NYSE: PFE) has announced positive topline results regarding overall survival (OS) in the...
CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has initiated...
KangaBio’s KGX101 Receives NMPA Approval for Clinical Trial in China
KangaBio, a biopharmaceutical company based in Shanghai, has announced that its investigational new drug (IND)...
Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials
JNJ-78278343, a KLK2-CD3 bispecific antibody, is currently in Phase I clinical trials globally. According to...
Merck KGaA’s Pergoveris Treatment Expands Access to Advanced Reproductive Care in Greater Bay Area
Merck KGaA (MRK, NYSE: MRK) , a leading science and technology company based in Germany,...
Junshi Biosciences’ Ongericimab Wins NMPA Nod for Hypercholesterolemia Treatment
Junshi Biosciences (HKG: 1877; SHA: 688180), a leading biopharmaceutical company in China, has announced that...
Juventas Cell Therapy’s CAR-T Therapy Clears for SLE-ITP Study in China
The China Center for Drug Evaluation (CDE) has given the green light for a study...
Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001
Immupeutics Medicine, a pioneer in tumor immunotherapy based in Beijing, has announced that it has...
Pfizer’s Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B
Pfizer Inc. (NYSE: PFE) has scored a significant win with the US Food and Drug...
Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market
Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...
Coherent Biopharma’s CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer
Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDCs) with operations in Suzhou, China,...
Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors
Doma Biopharmaceutical (Suzhou) Co., Ltd, a biotech firm with a presence in China and the...
Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Roche’s Genentech Scores FDA Approval for Itovebi in Advanced Breast Cancer Treatment, Advancing Personalized Oncology
Roche (SWX: ROG)’s Genentech, a leader in pharmaceutical innovation, has received approval from the US...
Johnson & Johnson’s Darzalex Combo Therapy Gets EMA Nod for Multiple Myeloma, Aims to Set New Standard
Johnson & Johnson (NYSE: JNJ) has taken a significant step in expanding its oncology portfolio...
Jiangsu Hengrui’s SHR2554 Gets Priority Review for Lymphoma Treatment, Strengthening Global EZH2 Inhibitor Market
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is on the brink of a breakthrough in...
Jiangsu Hengrui Secures FDA Nod for Generic Abraxane, Strengthening Oncology Portfolio
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has achieved a first in the US market...
Biogen Gains FDA Breakthrough Status for Felzartamab in Kidney Transplant Rejection Treatment
Biogen Inc. (NASDAQ: BIIB) has secured breakthrough therapy designation (BTD) from the U.S. Food and...